UC Pancreatic Cancer Consortium


clinical trials

Pancreas Cancer Clinical Trials across the UC System

upcoming events

UCPCC Seminar Series

and upcoming Symposia

funding opportunities

Open opportunities are listed below


UCPCC Seminar Series

All seminars are held on the first Tuesday of each month from 8:00-9:00 AM PT. 

December 6, 2022 8:00-9:00 AM

Speaker: Jaehoon Shin (UCSF)

Antigen-dependent inducible T cell reporter system for cancer PET imaging and therapy

Join the meeting using this link


Who We Are

The mission of the UC Pancreatic Cancer Consortium (UCPCC) is to unite scientists and clinicians across the UC cancer centers committed to pancreatic cancer research and treatment in a highly collaborative environment that accelerates the progress and impact of our work.

Our vision is to improve the lives of persons diagnosed with pancreatic cancer by translating innovative research into improved clinical care.

UCPCC UC Leaders: 
UC Davis Comprehensive Cancer Center – Richard Bold
UCI Chao Family Comprehensive Cancer Center – Murray Korc
UCLA Jonsson Comprehensive Cancer Center – Timothy Donahue
UC San Diego Moores Cancer Center – Andrew Lowy
UCSF Helen Diller Family Comprehensive Cancer Center – Margaret Tempero


Left to right; Dr’s Richard Bold, Andrew Lowy, Margaret Tempero, Tannishtha Reya, Julie Sutcliffe and Katie Couric at the Stand Up To Cancer 2019 Scientific Summit in Santa Monica, CA.

UC Pancreatic Cancer Consortium Working Groups:


  • Biobanking

  • Early Biology                                         

  • Early Detection

  • Imaging                                  

  • Inherited Susceptibility  

  • PDAC Clinical Trials

  • Technology Assessment

  • PNET

Funding Opportunities

The UC Pancreatic Cancer Consortium supports pilot projects to encourage collaboration between UC campuses. RFPs will be posted here.


For additional information or guidance, contact Kurt Giles (kurt.giles@ucsf.edu).

Pilot Awards:

  • 2022 

    • Development and Validation of an Artificial Intelligence Platform to Predict Negative-Margin (R0) Resectability of Pancreatic Ductal Adenocarcinoma Based on Preoperative CT Scans: Adnan Alseidi (UCSF) and Timothy Donahue (UCLA)

  • 2021

    • Germline Testing in Pancreatic Neuroendocrine Tumors: Mallika Dhawan and Emily Bergsland (UCSF), Joel (Randy) Hecht (UCLA), and Andrew Lowy (UCSD)

    • Defining the metabolic vulnerabilities of chemoresistant pancreatic cancer: Christopher Halbrook (UCI) and Herve Tiriac (UCSD)


Copyright 2021 © Regents of the University of California